NLRP3 and cryopyrin-associated periodic syndrome: Certain mutations hypersensitize NLRP3 to cold exposure and nigericin, and most CAPS-associated variants are responsive to the NLRP3 inhibitor MCC950 (also known as CP-456,773 and CRID3) [202].